Molecular Engineering of Bioactive Hydrogels
Molecular Engineering of Bioactive Hydrogels
批准号:
7595085
负责人:
DAVID V SCHAFFER
金额:
$17.25万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-04-01 至 2011-03-31
关键词:
AddressAdverse effectsAffinityAnimalsBindingBiologicalBiologyBiomedical EngineeringBrainCell CountCell Culture SystemCell Differentiation processCell physiologyCellsClinicalCoculture TechniquesCollectionComplexConditioned Culture MediaCongestive Heart FailureDevelopmentDiabetes MellitusDiseaseEngineeringEngraftmentEnvironmentEpitopesExtracellular MatrixExtracellular Matrix ProteinsGoalsGrantHeartHumanHydrogelsImmuneIn VitroInjuryLigandsLiverMedicineMethodsMolecularMolecular BiologyMusMusclePancreasParkinson DiseasePatientsPeptidesProcessProteinsRegenerative MedicineReproducibilityScienceSerumSignal TransductionSourceStem cellsSurfaceSystemTechnologyTissue EngineeringTissuesTreatment Efficacybasebonecell behaviorcell typehuman embryonic stem cellimmunogenicin vivolarge scale productionleukemianovelpathogenpublic health relevancereconstructionscale upself-renewalstem cell biologystem cell populationsynthetic peptidetherapy designtransmission process
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Description (provided by applicant): Human embryonic stem cells (hESCs) have strong potential as sources of cells for the treatment for disease and injury (e.g. tissue engineering and reconstruction, diabetes, Parkinson's Disease, leukemia, congestive heart failure, etc.). The successful integration of hESC into such therapies will hinge upon three critical steps: their expansion without differentiation (i.e., self-renewal), their differentiation into a specific cell type or collection of cell types, and the promotion of their survival and functional integration into existing tissue. However, controlling cell behavior during each of these steps will require precise control over the cellular microenvironment. This poses a major challenge ex vivo in current hESC culture systems, which range from co-culture with feeder cells to serum-free systems where cells are cultured on complex extracellular matrix proteins. All such systems involve animal or human proteins, which pose problems for pathogen transmission, immune rejection, limited reproducibility, and scale up to a clinical process. To achieve the intended goals of regenerative medicine, methods for the precise control of the survival, proliferation, and differentiation of stem cell populations in vitro and in vivo are necessary. Here, we propose to develop a completely synthetic environment to precisely control hESC self-renewal in culture. Specifically, we will engineer a tunable and well-defined environment presenting a completely "synthetic extracellular matrix" (ECM) and chemically-defined media to control the self-renewal/expansion of hESCs. Furthermore, we will
develop high throughput approaches to identify synthetic peptide ligands for functionalization to the synthetic ECM and promotion of hESC self-renewal. If hESCs can be derived and maintained within this fully synthetic microenvironment, then it will be possible to eliminate pathogen transmission associated with mouse or human feeder layers, provide a scalable basis for large-scale production of hESCs, and provide a precise base for further development to control hES cell differentiation. Furthermore, the result will be a technology platform that can be generally applied to numerous stem cell populations and used to investigate the basic biological/developmental mechanisms underlying self-renewal. Public Health Relevance: The development of novel, bioactive materials has significant potential for exerting precise control over cell function, both for fundamental biological studies and applications in tissue engineering and regenerative medicine. For example, developing synthetic, bioactive material systems to promote the self-renewal and expansion of human embryonic stem cells will have numerous biomedical applications including the design of therapies for disease or injury in the muscle, bone, brain, heart, liver, pancreas, and other tissues. The novel blend of stem cell biology, materials science, molecular biology, and bioengineering described in this proposal will be well suited to addressing an important problem, i.e. stem cell control, at the interface of biology, engineering, and medicine
期刊论文(5)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1016/j.biomaterials.2010.07.104
发表时间:
2010-11
期刊:
BIOMATERIALS
影响因子:
14
作者:
[Ananthanarayanan, Badriprasad, Little, Lauren, Schaffer, David V., Healy, Kevin E., Tirrell, Matthew]
通讯作者:
Tirrell, Matthew
DOI:
10.1016/j.tibtech.2009.11.008
发表时间:
2010-03
期刊:
Trends in biotechnology
影响因子:
17.3
作者:
[T. Vazin;D. Schaffer]
通讯作者:
T. Vazin;D. Schaffer
Biology and Biotechnology of Cell and Gene Therapy
-
批准号:10090424
-
项目类别:
-
资助金额:$35.65万
-
财政年份:2021
-
负责人:DAVID V SCHAFFER
-
依托单位:
In Vivo Directed Evolution of Adeno-Associated Virus Vectors for Glioblastoma Multiforme Tumor-Initiating Cells
-
批准号:9353802
-
项目类别:
-
资助金额:$22.46万
-
财政年份:2016
-
负责人:DAVID V SCHAFFER
-
依托单位:
Molecular Engineering of Bioactive Hydrogels
-
批准号:7471860
-
项目类别:
-
资助金额:$21.0万
-
财政年份:2008
-
负责人:DAVID V SCHAFFER
-
依托单位:
Engineering AAV Vectors to Evade Antibody Neutralization
-
批准号:7849654
-
项目类别:
-
资助金额:$43.63万
-
财政年份:2007
-
负责人:DAVID V SCHAFFER
-
依托单位:
Engineering AAV Vectors to Evade Antibody Neutralization
-
批准号:7442123
-
项目类别:
-
资助金额:$36.12万
-
财政年份:2007
-
负责人:DAVID V SCHAFFER
-
依托单位:
Engineering AAV Vectors to Evade Antibody Neutralization
-
批准号:7208807
-
项目类别:
-
资助金额:$37.66万
-
财政年份:2007
-
负责人:DAVID V SCHAFFER
-
依托单位:
Engineering AAV Vectors to Evade Antibody Neutralization
-
批准号:7626787
-
项目类别:
-
资助金额:$36.07万
-
财政年份:2007
-
负责人:DAVID V SCHAFFER
-
依托单位:
Engineering AAV Vectors to Evade Antibody Neutralization
-
批准号:7851669
-
项目类别:
-
资助金额:$7.99万
-
财政年份:2007
-
负责人:DAVID V SCHAFFER
-
依托单位:
Engineering Novel AAV Vectors for Retinal Gene Therapy
-
批准号:7268010
-
项目类别:
-
资助金额:$17.93万
-
财政年份:2006
-
负责人:DAVID V SCHAFFER
-
依托单位:
Engineering Novel AAV Vectors for Retinal Gene Therapy
-
批准号:7149417
-
项目类别:
-
资助金额:$21.69万
-
财政年份:2006
-
负责人:DAVID V SCHAFFER
-
依托单位:
Stochastic Gene Expression Effects in a Model Retrovirus
-
批准号:6970261
-
项目类别:
-
资助金额:$27.09万
-
财政年份:2005
-
负责人:DAVID V SCHAFFER
-
依托单位:
Stochastic Gene Expression Effects in a Model Retrovirus
-
批准号:7455760
-
项目类别:
-
资助金额:$27.53万
-
财政年份:2005
-
负责人:DAVID V SCHAFFER
-
依托单位:
Stochastic Gene Expression Effects in a Model Retrovirus
-
批准号:7080397
-
项目类别:
-
资助金额:$28.4万
-
财政年份:2005
-
负责人:DAVID V SCHAFFER
-
依托单位:
Stochastic Gene Expression Effects in a Model Retrovirus
-
批准号:7248589
-
项目类别:
-
资助金额:$27.56万
-
财政年份:2005
-
负责人:DAVID V SCHAFFER
-
依托单位:
Engineering Molecular Sensors for Stem Cell Function
-
批准号:6879693
-
项目类别:
-
资助金额:$16.8万
-
财政年份:2004
-
负责人:DAVID V SCHAFFER
-
依托单位:
Engineering Molecular Sensors for Stem Cell Function
-
批准号:6759089
-
项目类别:
-
资助金额:$16.09万
-
财政年份:2004
-
负责人:DAVID V SCHAFFER
-
依托单位:
Molecular Engineering of AAV for Stealth and Targeting
-
批准号:6736556
-
项目类别:
-
资助金额:$19.83万
-
财政年份:2003
-
负责人:DAVID V SCHAFFER
-
依托单位:
Molecular Engineering of AAV for Stealth and Targeting
-
批准号:6797398
-
项目类别:
-
资助金额:$14.59万
-
财政年份:2003
-
负责人:DAVID V SCHAFFER
-
依托单位:
GROWTH FACTOR SIGNALING AND NEURAL PROGENITOR CELL FATE
-
批准号:2711330
-
项目类别:
-
资助金额:$2.5万
-
财政年份:1998
-
负责人:DAVID V SCHAFFER
-
依托单位:
Applied Biology and Bioprocess Engineering Training
-
批准号:7257878
-
项目类别:
-
资助金额:$25.9万
-
财政年份:1989
-
负责人:DAVID V SCHAFFER
-
依托单位:
海外基金